Sunrise

Sunrise specializes in two primary categories of devices: home-use sleep apnoea recording systems and professional-only sleep disorder interpretive software. The home-use systems allow patients to track their breathing patterns and sleep quality independently, while the software assists healthcare providers in analyzing sleep disorder data for diagnostic purposes. These devices are designed to support the identification and management of sleep-related conditions.

Sunrise is based in the United States. Since the company operates within the US, its devices are subject to FDA regulations. The FDA classifies Sunrise’s devices as Class II, which typically requires premarket submissions like 510(k) notifications and compliance with the Unique Device Identifier (UDI) system to ensure safety and effectiveness before they enter the market.

Sunrise’s devices are listed in the FDA’s 510(k) premarket notification database and the Unique Device Identifier (UDI) system. These registries ensure transparency and traceability of medical devices by documenting their regulatory clearance and identification details. The 510(k) process demonstrates that the devices meet FDA requirements for safety and performance, while the UDI system provides a standardized way to identify devices throughout their lifecycle.

Sunrise’s devices are classified as FDA Class II. This classification indicates a moderate level of risk, requiring specific regulatory controls like 510(k) clearance and compliance with manufacturing standards to ensure their safety and effectiveness. Class II classification helps balance oversight with innovation, ensuring that devices like sleep apnoea monitors and diagnostic software meet necessary standards without unnecessary regulatory burdens.